Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(14):1028-1029; doi:10.1093/jnci/dji225
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

New Studies Look Beyond EGFR Mutations for Clues to Sensitivity to Erlotinib

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

The approval of erlotinib (Tarceva) in November 2004 was based on the results of a randomized, placebo-controlled trial called BR.21, in which the drug improved overall survival for patients with non–small-cell lung cancer who had already been treated with one or two chemotherapy regimens. Despite the survival benefit, only a small percentage of patients showed substantial tumor shrinkage in response to the drug.

When data from BR.21 were released in May 2004, it appeared that erlotinib would follow in the path of another epidermal growth factor receptor (EGFR) inhibitor, gefitinib (Iressa)—that researchers would find that patients with EGFR mutations would be the best responders. However, a retrospective analysis of the trial, presented this May at the annual meeting of the American Society of Clinical Oncology, shows that's not likely to be the case. Those data leave open the question of why only . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?